NASDAQ:LGNDLigand Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Ligand Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $81.54 +3.31 (+4.23 %) (As of 04/8/2020 01:44 PM ET) Add Compare Share Today's Range$78.47Now: $81.54▼$84.9350-Day Range$63.37MA: $86.76▼$107.8852-Week Range$57.24Now: $81.54▼$130.50Volume25,791 shsAverage Volume529,946 shsMarket Capitalization$1.35 billionP/E Ratio2.78Dividend YieldN/ABeta1.4 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations; bazedoxifene for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta for non-small cell lung cancer. The company's partners programs, which are in clinical development used for the treatment of seizure, coma, cancer, diabetes, cardiovascular diseases, muscle wasting, liver and kidney diseases, and others. It is also developing a small molecule glucagon receptor antagonist for the treatment of Type 2 diabetes mellitus. In addition, the company is involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in San Diego, California.Read More Beat the Market (BTM) Rank™ 4.3 Analyst's Opinion Consensus RatingLigand Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $163.20, Ligand Pharmaceuticals has a potential upside of 100.1% from its current price of $81.54.Amount of Analyst CoverageLigand Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.9 Community Rank Outperform VotesLigand Pharmaceuticals has received 491 “outperform” votes. (Add your “outperform” vote.)Underperform VotesLigand Pharmaceuticals has received 365 “underperform” votes. (Add your “underperform” vote.)Community SentimentLigand Pharmaceuticals has received 57.36% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Ligand Pharmaceuticals and other stocks. Vote “Outperform” if you believe LGND will outperform the S&P 500 over the long term. Vote “Underperform” if you believe LGND will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldLigand Pharmaceuticals does not currently pay a dividend.Dividend GrowthLigand Pharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ligand Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,487,194.00 in company stock.Percentage Held by InsidersOnly 8.40% of the stock of Ligand Pharmaceuticals is held by insiders. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Ligand Pharmaceuticals are expected to grow by 22.03% in the coming year, from $2.27 to $2.77 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ligand Pharmaceuticals is 2.78, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 12.20.Price to Earnings Ratio vs. SectorThe P/E ratio of Ligand Pharmaceuticals is 2.78, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 20.74.Price to Earnings Growth RatioLigand Pharmaceuticals has a PEG Ratio of 2.15. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioLigand Pharmaceuticals has a P/B Ratio of 1.87. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.3Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 2.5 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.95 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:LGND Previous Symbol CUSIP53220K50 CIK886163 Webhttp://www.ligand.com/ Phone858-550-7500Debt Debt-to-Equity Ratio0.85 Current Ratio66.09 Quick Ratio65.66Price-To-Earnings Trailing P/E Ratio2.78 Forward P/E Ratio35.92 P/E Growth2.15 Sales & Book Value Annual Sales$120.28 million Price / Sales11.19 Cash Flow$6.66 per share Price / Cash Flow12.24 Book Value$43.68 per share Price / Book1.87Profitability EPS (Most Recent Fiscal Year)$2.11 Net Income$629.30 million Net Margins523.19% Return on Equity4.34% Return on Assets2.40%Miscellaneous Employees116 Outstanding Shares16,505,000Market Cap$1.35 billion Next Earnings Date5/6/2020 (Confirmed) OptionableOptionable Receive LGND News and Ratings via Email Sign-up to receive the latest news and ratings for LGND and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:LGND Rates by TradingView Ligand Pharmaceuticals (NASDAQ:LGND) Frequently Asked Questions How has Ligand Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Ligand Pharmaceuticals' stock was trading at $91.83 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, LGND shares have decreased by 11.2% and is now trading at $81.54. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Ligand Pharmaceuticals? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ligand Pharmaceuticals in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Ligand Pharmaceuticals. When is Ligand Pharmaceuticals' next earnings date? Ligand Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, May 6th 2020. View our earnings forecast for Ligand Pharmaceuticals. How were Ligand Pharmaceuticals' earnings last quarter? Ligand Pharmaceuticals Inc. (NASDAQ:LGND) released its earnings results on Thursday, February, 6th. The biotechnology company reported $0.71 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.64 by $0.07. The biotechnology company earned $27 million during the quarter, compared to the consensus estimate of $25.30 million. Ligand Pharmaceuticals had a return on equity of 4.34% and a net margin of 523.19%. The firm's quarterly revenue was down 54.7% compared to the same quarter last year. During the same period last year, the firm earned $1.70 earnings per share. View Ligand Pharmaceuticals' earnings history. What guidance has Ligand Pharmaceuticals issued on next quarter's earnings? Ligand Pharmaceuticals updated its FY 2020 Pre-Market earnings guidance on Thursday, February, 27th. The company provided earnings per share guidance of 3.62-3.62 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.47. The company issued revenue guidance of $133-133 million, compared to the consensus revenue estimate of $125.82 million. What price target have analysts set for LGND? 6 analysts have issued 1-year price objectives for Ligand Pharmaceuticals' shares. Their forecasts range from $132.00 to $229.00. On average, they expect Ligand Pharmaceuticals' stock price to reach $163.20 in the next year. This suggests a possible upside of 100.1% from the stock's current price. View analysts' price targets for Ligand Pharmaceuticals. What are Wall Street analysts saying about Ligand Pharmaceuticals stock? Here are some recent quotes from research analysts about Ligand Pharmaceuticals stock: 1. According to Zacks Investment Research, "Ligand reported encouraging second-quarter results with earnings and sales beating estimates. The company’s Captisol Formulation technology resulted in partnerships with several leading drug companies like Novartis and Amgen that provide it with funds in the form of milestone and royalty payments. Ligand is acquiring other technology platforms like OmniAb platform from OMT acquisition to reduce dependence on Captisol formulation. OmniAb is likely to drive future revenues. However, Shares of Ligand have underperformed the industry so far this year. Moreover, Ligand derives a substantial portion of its revenues from royalties associated with the sales of Kyprolis. Any setback to Kyprolis will have an unfavorable impact on the top line. Moreover, increase in inactive licensing deals related to Ligand’s technology platform raises concerns." (8/8/2019) 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and $214 price target. Our target is based on sum of the parts including: (1) a clinical NPV model of assets in Phase 2 development or greater (currently 30 out of over 200 assets under development); and (2) NPV of current revenues based on our projections for royalties, material sales, and collaborative revenue." (5/3/2019) Has Ligand Pharmaceuticals been receiving favorable news coverage? Media stories about LGND stock have been trending very negative this week, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Ligand Pharmaceuticals earned a news impact score of -3.3 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news aboutLigand Pharmaceuticals. Are investors shorting Ligand Pharmaceuticals? Ligand Pharmaceuticals saw a increase in short interest in March. As of March 13th, there was short interest totaling 8,904,900 shares, an increase of 12.6% from the February 27th total of 7,910,000 shares. Based on an average daily volume of 632,600 shares, the short-interest ratio is presently 14.1 days. Currently, 56.1% of the shares of the stock are short sold. View Ligand Pharmaceuticals' Current Options Chain. Who are some of Ligand Pharmaceuticals' key competitors? Some companies that are related to Ligand Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), Neurocrine Biosciences (NBIX), EXACT Sciences (EXAS), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL). What other stocks do shareholders of Ligand Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ligand Pharmaceuticals investors own include Jazz Pharmaceuticals (JAZZ), NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Illumina (ILMN), Netflix (NFLX), Intel (INTC), AbbVie (ABBV), Cisco Systems (CSCO) and Gilead Sciences (GILD). Who are Ligand Pharmaceuticals' key executives? Ligand Pharmaceuticals' management team includes the following people: Mr. John L. Higgins, CEO & Exec. Director (Age 49)Mr. Matthew W. Foehr, Pres & COO (Age 46)Mr. Matthew Korenberg, Exec. VP of Fin. & CFO (Age 44)Mr. Charles S. Berkman, Sr. VP, Gen. Counsel & Sec. (Age 50)Mr. Todd Pettingill, Director of Corp. Devel. What is Ligand Pharmaceuticals' stock symbol? Ligand Pharmaceuticals trades on the NASDAQ under the ticker symbol "LGND." Who are Ligand Pharmaceuticals' major shareholders? Ligand Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Woodstock Corp (0.43%). Company insiders that own Ligand Pharmaceuticals stock include Charles S Berkman, Jason Aryeh, John L Higgins, John L Lamattina, John W Kozarich, Matthew E Korenberg, Matthew W Foehr, Sunil Patel and Todd C Davis. View institutional ownership trends for Ligand Pharmaceuticals. Which institutional investors are selling Ligand Pharmaceuticals stock? LGND stock was sold by a variety of institutional investors in the last quarter, including Woodstock Corp. View insider buying and selling activity for Ligand Pharmaceuticals. How do I buy shares of Ligand Pharmaceuticals? Shares of LGND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Ligand Pharmaceuticals' stock price today? One share of LGND stock can currently be purchased for approximately $81.54. How big of a company is Ligand Pharmaceuticals? Ligand Pharmaceuticals has a market capitalization of $1.35 billion and generates $120.28 million in revenue each year. The biotechnology company earns $629.30 million in net income (profit) each year or $2.11 on an earnings per share basis. Ligand Pharmaceuticals employs 116 workers across the globe. View additional information about Ligand Pharmaceuticals. What is Ligand Pharmaceuticals' official website? The official website for Ligand Pharmaceuticals is http://www.ligand.com/. How can I contact Ligand Pharmaceuticals? Ligand Pharmaceuticals' mailing address is 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-550-7500 or via email at [email protected] This page was last updated on 4/8/2020 by MarketBeat.com StaffFeatured Article: Why are percentage gainers important?
